Examples include the treatment of recurrent PTPRZ1-MET fusion-positive glioblastoma using the MET kinase inhibitor crizotinib, KIAA1549-BRAF fusion driven pediatric pilocytic astrocytoma treatment using the MEK inhibitor trametinib, and ALK-EML4 fusion-positive lung cancer using tyrosine kinase inhibitor lorlatinib (Bender et al., 2016; Jain et al., 2017; Shaw et al., 2019). This evidence concerns the gene KIAA1549 and pilocytic astrocytoma.